Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

BACKGROUND: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the 5-year survival rate in patients diagnosed a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Pal, Sumanta, Gong, Jun, Mhatre, Shivani K., Lin, Shih-Wen, Surinach, Andy, Ogale, Sarika, Vohra, Rini, Wallen, Herschel, George, Daniel
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555983/
https://ncbi.nlm.nih.gov/pubmed/31174493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5716-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars